Trial Profile

Phase I open-label study of Lenalidomide subcutaneous for treatment of late-stage chronic lymphocytic leukemia (CLL) patients

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Sep 2021 According to a Starton Therapeutics media release, STAR-LLD SC is expected to enter clinical studies in Q1 2022. The company has completed a pre-IND meeting for STAR-LLD SC and all IND-enabling studies.
11 Jan 2021 According to a Starton Therapeutics media release, STAR-LLD SC clinical trial materials are expected to be shipped in Q2 2021 for initiation of Phase 1/2 clinical studies for CLL in the second half of 2021.
08 May 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com